Back to All

The Microbiome, Inflammation, and Cancer

Cancer and Autoimmune Disorders

Presented by: Mark Rosenberg, MD

Original Presentation Date: September 15, 2017

Take the Course This course is available for CE Credit as a "Members Only" benefit. Not a Member? CLICK HERE to learn more about AAOSH Membership.


Course Description:

This lecture will present data revealing the link between our microbiome, inflammation, and cancer. Although the microbiome of the oral cavity differs from that of the lower GI tract, alterations in either or both can lead to chronic inflammation and predisposition to chronic disease and cancer. Following a discussion of dysbiosis, impaired immune function, and cancer predisposition, we will discuss various modalities for repairing immune function, as well as treating cancer.

Learning Objectives:

  • Analyze the correlation between dysbiosis, compromised immune function, and their association with cancer development, demonstrating an understanding of the underlying biological mechanisms.
  • Evaluate the empirical evidence highlighting the relationship between periodontal disease and various cancer types, fostering familiarity with pertinent data to assess their interconnectedness within healthcare contexts.
  • Assess the available data concerning the restoration of wellness by addressing and repairing the microbiome, demonstrating an understanding of how microbiome repair contributes to overall health improvement.
  • Critically analyze the existing research on the impact of fasting on immune function, demonstrating familiarity with the data and its implications for enhancing immune response and overall health.

Speaker Bio:

Dr. Mark Rosenberg, initially trained in emergency medicine, underwent a transformative experience approximately 14 years ago while practicing in the emergency department when he diagnosed his mother with metastatic lung cancer—her passing nine months later prompted Dr. Rosenberg to delve into the study of tumor metabolism. This journey led him to assume the role of program director for the inaugural integrative cancer fellowship. Transitioning into the domain of cancer science, Dr. Rosenberg established a pharmaceutical company focused on pioneering drugs tailored to target cancer stem cells, advancing the forefront of cancer treatment.